Iantrek announces first commercial cases of C.Rex micro-interventional system

News
Article

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.

Technological graphic of eye Image credit: AdobeStock/ImageFlow

Image credit: AdobeStock/ImageFlow

Medical technology company Iantrek has announced the first commercial cases of its micro-interventional system for canal outflow enhancement designed for glaucoma surgery.1 The cases are part of the company’s pre-launch activities that features the C.Rex technology, used as an ophthalmic surgical system for canal outflow gonio-intervention, according to a news release.

“All conventional approaches have focused on the trabecular meshwork and the inner canal wall,” said Carol Toris, PhD, professor at the University of Nebraska Medical Center, in the release. “We have shown empirically and presented our study at ARVO that dual canal intervention can lead to incremental outflow enhancement over single inner wall goniotomy. Iantrek’s approach is uniquely original as it is able to address outflow resistance in the entire canal.”

C.Rex is a super-elastic nitinol filament technology and remains the only FDA-registered MIGS technology for excisional circumferential trabeculorhexis and dual wall canal intervention. The nitinol filament technology allows for flexible micro-instrumentation with memory-shaped super-elasticity to deliver 360-degrees of excisional, single, or dual wall canalotomy. C.Rex is also the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.1

“There are a lot of trabecular technologies, but this is an interventional breakthrough in non-implantable trabecular outflow surgery,” said Arkadidy Yadgarov, MD, of OMNI Eye Services in Atlanta, GA, and the first surgeon in the country to utilize the advanced technology, in the release. “It is one of the most surgically intuitive MIGS technologies, and the only goniotomy system to enable surgical intervention on the entire canal, not just segmentally. The C.Rex offers circumferential excisional goniotomy which is guided, continuous, comprehensive and can reduce resistant in the outer wall.”

Reference:
  1. Iantrek announces first commercial cases of its C.Rex micro-interventional system for trabecular outflow enhancement. News release. Iantrek. January 13, 2025. Accessed February 3, 2025. https://iantrekmed.com/iantrek-announces-first-commercial-cases-of-its-c-rex-micro-interventional-system-for-trabecular-outflow-enhancement/

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
© 2025 MJH Life Sciences

All rights reserved.